FDA Approves Treatment for Moderate-to-Severe Chronic Hand Eczema
Regulatory approval is based on clinical trials showing improvements in symptom severity and treatment success at 16 weeks.
Regulatory approval is based on clinical trials showing improvements in symptom severity and treatment success at 16 weeks.
The ready-to-use liquid botulinum toxin treatment requires no reconstitution. Phase III trials showed improvements in frown lines, with some patients maintaining results for up to six months.